Caixin
Jul 16, 2022 04:24 AM
TECH

Genuine Biotech Reports Unimpressive Results for Covid Pill

China’s domestic drugmakers are rushing to develop their own Covid treatments.
China’s domestic drugmakers are rushing to develop their own Covid treatments.

Chinese drugmaker Genuine Biotech reported unimpressive trial results for its Azvudine Covid treatment, prompting a sell-off in related drug stocks.

The response reflected concerns that Azvudine’s clinical trial results fell short of regulatory recommendations. While privately held Genuine Biotech said the drug improved clinical symptoms, Chinese regulators in a February guideline said Covid-19 treatments should reduce severe illness and death.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin China Biz Roundup: China Cuts Key Interest Rates as Economy Weakens
00:00
00:00/00:00